EU SolidAct, a new platform trial for emerging pandemics, today starts testing new drugs for severe COVID-19, aiming to improve treatment options and to strengthen European pandemic preparedness bit.ly/EU_SolidAct / EU-SolidAct / ECRIN / Inserm / EU Science & Innovation 🇪🇺

EU-SolidAct Baricitinib is in the house! Aleksander has everything ready and set to include the first patient!

Den nye Europeiske plattformstudien for COVID-19 og fremtidige pandemier, EU-SolidAct, har nå startet å inkludere pasienter ved norske sykehus. Studien skal gå i 15 land og ledes av OUS. bit.ly/EU_SolidAct / EU-SolidAct / ECRIN / Inserm/ EU Science & Innovation 🇪🇺

Happy to inform that the two first patients are included, the first at the world's northernmost university hospital UNN with PI A Kildal and the second in @SykehusVestfold with PI Asgeir Johannessen! EU Science & Innovation 🇪🇺 / ECRIN / Oslounivsykehus / Inserm

Baricitinib/placebo has arrived LovisenbergSykehus! Simen Walberg Schive and colleagues are ready to include their first patient in the Trial as the eight European site.

Happy to inform that we have now reached 100 randomised patients! We are recruiting in 33 sites in 5 countries, with more to follow. EU Science & Innovation 🇪🇺/ECRIN/Oslounivsykehus/ Inserm

New paper from the DisCoVeRy and the EU-SolidAct EU-RESPONSE group with Departement Klinische Forschung, Universität Basel contribution by Matthias Briel: "Europe, despite its diversity, must be capable of responding unanimously and rapidly to any health crisis": bit.ly/3HPM3yE #platformtrial #COVID19

Happy to inform that Belgium and Luxembourg have now included their first patients, making them the 6th and 7th country with more to come!

Happy to inform that we have now reached 200 randomised patients! We have opened 45 sites in 10 countries, with more to follow. EU Science & Innovation 🇪🇺 / ECRIN / Oslounivsykehus / Inserm

Now Austria and and the Medical University of Innsbruck has included their first patient in the EU-SolidAct trial on Baricitinib treatment EU Science & Innovation 🇪🇺/ECRIN/Oslounivsykehus/Inserm

We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the EU-SolidAct trial. Read the release here: bergenbio.com/investors/stoc… #AXL

DMC/DSMB members do very valuable and mostly unappreciated work in RCTs. Thank you very much drs. STEFANO VELLA, Du, Medaglini, Jacobs, vd Werf, Medaglini, Stuart Pocock, Phaik Yeong Cheah, Barnes, Yeni and Collier for excellent work in our DMC!

Results of the Bari-SolidAct clinical trial, conducted in 14 European countries, have been published in Critical Care. eu-response.eu/eu-solidact-pu… pubmed.ncbi.nlm.nih.gov/36627655/

🆕#IPDMA on #JAKinhibitors in #COVID19 patients in🏥. Many trials were conducted, but several❓❔❓ unanswered -> jakinhibitoripdma.org In collaboration with Oslo Centre for Biostatistics and Epidemiology, The Division of Clinical Epidemiology Basel, Inserm, a patient representative, EU-SolidAct and 10 other participating trial teams